#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
medScope.pro

News

nežádoucí účinky leukémie

Management of Adverse Effects During Maintenance Treatment of AML Patients

4. 9. 2023 Source: Acute Myeloid Leukemia

The randomized phase III study QUAZAR AML-001 evaluated the maintenance treatment of acute myeloid leukemia (AML) in patients after first remission. The following text summarizes the findings regarding the most common adverse events (AEs) in this therapy and practical recommendations for managing side effects based on guidelines from professional societies.

osteoporoza

SCOPE 2021 –⁠ State of Osteoporosis and Its Treatment in European Countries

The SCOPE 2021 project (The Scorecard for Osteoporosis in Europe) by the International Osteoporosis Foundation (IOF) gathered and tabulated data from 29 European countries on the burden of…
4. 9. 2023 Source: Osteoporosis – Trends in Sequential Therapy
zenaulekare

Risk of Subsequent Fractures in Postmenopausal Women After Initial Fracture

Osteoporosis is associated with an increased risk of fractures. The prospective analysis presented below examined the risk of subsequent fractures in postmenopausal women after an initial fracture…
4. 9. 2023 Source: Osteoporosis – Trends in Sequential Therapy
dívka s atopickou dermatitidou na rukou

Laboratory Safety of Dupilumab Treatment in Children with Atopic Dermatitis Aged 6 Months to 6 Years

Previous clinical studies in children aged 6–12 years with moderate-to-severe atopic dermatitis have demonstrated laboratory safety during dupilumab treatment. The randomized study presented below…
1. 9. 2023 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation
mozek

Long-term Safety and Efficacy of Ozanimod in the Treatment of Relapsing Forms of MS

Ozanimod is classified as a modulator of sphingosine-1-phosphate (S1P) receptors types 1 and 5. It is approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) and moderate to…
28. 8. 2023 Source: Modulation of S1P in the Treatment of Autoimmune Diseases
srdce a cukrovka

How does empagliflozin perform in older type 2 diabetics compared to liraglutide and sitagliptin in terms of HHF and MACE risks?

Last fall, a study was published in JAMA Network Open, focusing on older patients with type 2 diabetes mellitus (DM2), examining the cardiovascular risk impact when treated with empagliflozin,…
28. 8. 2023 Source: Diabetes
vakcina dite naplast

Prof. Roman Chlíbek: Role of Multivalent Pneumococcal Conjugate Vaccines in Healthy and Premature Children

Children are frequent carriers of pneumococci, which can cause both common non-invasive and more severe, life-threatening invasive pneumococcal diseases, especially in children under 1 year of age…
25. 8. 2023 Source: Regular Vaccination
nemocnice

Hereditary Angioedema as a Clinical Picture of Excessive Activation of the Kinin Cascade –⁠ Case Report

Painful and potentially life-threatening swellings are characteristic of hereditary angioedema (HAE), a rare genetically determined disease. Dutch authors present in a recently published review the…
25. 8. 2023 Source: Hereditary Angioedema
Měření ejekční frakce

Efficacy of Empagliflozin in HFpEF Patients –⁠ Comparison of Subpopulations with Preserved and Mid-Range LV EF

A sub-analysis of the EMPEROR-Preserved clinical trial examined the effects and safety of empagliflozin in patients with heart failure with a left ventricular ejection fraction (LV EF) > 40%. What…
24. 8. 2023 Source: Heart Failure
artritida cislo 1

EULAR 2023: How does tofacitinib affect cardiovascular risk in rheumatoid arthritis?

At this year's European League Against Rheumatism (EULAR) congress, held at the turn of May and June in Milan, Italy, a study was presented that examined the impact of tofacitinib use on…
23. 8. 2023 Source: Arthritis
Ceftazidim/avibaktam (CZA)1

Efficacy of Ceftazidime/Avibactam in the Treatment of Infections Caused by Carbapenemase-Producing Enterobacteria

Infections caused by carbapenemase-producing enterobacteria are associated with high mortality, and their incidence continues to rise. The study presented below investigated the efficacy of therapy…
22. 8. 2023 Source: Anti-Infectives
artritida cislo 2

EULAR 2023: What Do CRP Levels Reveal About the Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis?

What is the impact of baseline C-reactive protein (CRP) levels on the efficacy and safety of treating ankylosing spondylitis (AS) with the Janus kinase inhibitor (JAKi) tofacitinib? The authors of…
22. 8. 2023 Source: Arthritis
uceloznikolitida

Long-term treatment of ozanimod in patients with moderate to severe ulcerative colitis

The immunosuppressive ozanimod was approved for the treatment of ulcerative colitis (UC) based on the results of the phase III clinical trial True North. An open-label study followed this and…
21. 8. 2023 Source: Modulation of S1P in the Treatment of Autoimmune Diseases
Nefrotiliáza - bolest pacienta

Can SGLT2 Inhibition Also Reduce the Risk of Nephrolithiasis?

Diabetes mellitus (DM) is a risk factor for the development of nephrolithiasis. Recent studies associated with nephrolithiasis suggest a possible beneficial effect of sodium-glucose cotransporter 2…
21. 8. 2023 Source: Diabetes
roztrousenaskleroza_mozek

MS in the Digital Age: Doctor as a Lifebuoy in the Sea of Information

How to offer a helping hand to patients amidst the flood of information and why is communication perhaps more important than ever? And what should the standards in the doctor-patient relationship…
15. 8. 2023 Source: Multiple Sclerosis
1 … 24 25 26 27 28 … 115
Filter by speciality
Remove filters
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#